Previously stated that data from clinical trials of the Company's late-stage compounds, tesetaxel and Genasense® (oblimersen sodium) Injection, will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from June 4-9, 2010 in Chicago, IL. Titles, dates, and times of these presentations are detailed below.
* Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone. (Abstract
#8573). Sunday June 6, 2010. Poster Session: Melanoma/Skin Cancers: 8 AM – 12 PM.
* Relation between baseline LDH and tumor burden in advanced melanoma in two phase III trials of oblimersen-dacarbazine (OBL-DTIC) vs. DTIC. (Abstract
#8557). Sunday June 6, 2010. Poster Session: Melanoma/Skin Cancers: 8 AM – 12 PM.
* Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma. (Abstract
#8561). Sunday June 6, 2010. Poster Session: Melanoma/Skin Cancers: 8 AM – 12 PM.
* An inter-subject dose-escalation study of tesetaxel administered orally once every 3 weeks and once weekly for 3 consecutive weeks in patients with advanced or metastatic solid tumors. (Abstract #TPS159). Monday June 7, 2010. Poster Session: Clinical Trials, Special Session: 8 AM – 12 PM.
* Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding agent. (Publication only).
www.toonicestocks.com/news/...techs-high-alert-asco-conference der gewinner hat viele freunde, der verlierer nur gute!